GENE ONLINE|News &
Opinion
Blog

2021-11-18| M&A

Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion

by Rajaneesh K. Gopinath
Share To
In November 2019, Dicerna Pharmaceuticals entered a strategic collaboration with Danish multinational pharma, Novo Nordisk to discover and develop novel therapies for liver-related cardio-metabolic diseases using its GalXC technology. The deal aimed to explore more than 30 liver cell targets and develop clinical candidates for a multitude of disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. 

Almost exactly two years later, Novo Nordisk has decided to completely acquire the Lexington, MA-based biotech in an all-cash deal for $38.25 per share that amounts to a total of $3.3 billion in equity value. This represents a premium of almost 80% to Dicerna's closing price on Wednesday. The M&A deal is expected to close in the fourth quarter of 2021, said the company in a statement. It also expects to initiate clinical development with the first target next year.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!